Regeneron Pharmaceuticals (REGN) Retained Earnings (2009 - 2026)

Regeneron Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $36.4 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 12.47% year-over-year to $36.4 billion; the TTM figure through Mar 2026 stood at $36.4 billion (up 12.47% YoY), while the FY2025 annual figure was $77.5 million, down 99.76% from the prior year.
• Retained Earnings was $36.4 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $77.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $36.4 billion in Q1 2026 to a low of -$275.1 million in Q3 2022.
• Historically, Retained Earnings has averaged $16.0 billion across 5 years, with a median of $23.3 billion in 2022.
• Biggest YoY gain for Retained Earnings was 89056.87% in 2022; the steepest drop was 101.64% in 2022.
• A 5-year view of Retained Earnings shows it stood at $23.3 billion in 2022, then advanced by 16.96% to $27.3 billion in 2023, then increased by 16.19% to $31.7 billion in 2024, then sank by 99.76% to $77.5 million in 2025, then jumped by 46898.45% to $36.4 billion in 2026.
• The last three Retained Earnings figures came in at $36.4 billion (Q1 2026), $77.5 million (Q4 2025), and $35.0 billion (Q3 2025), per Business Quant data.